Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... announced an important workshop at its new True North Conference Center. The medical ... so that the Jacksonville community may be more aligned in the effort to ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
(Date:7/31/2015)... ... 2015 , ... Cosmetic Town has proven itself as the ... surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. ... fillers. , Staying up to date with the latest cosmetic trends has ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Transfinder, a ... 2015. , Total sales were up 16 percent year-over-year for the first six months ... Antonio Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2
... Translational Science Institute (CTSI) and Tufts University today announced ... from the National Institutes of Health. These new ... original Clinical and Translational Science Award (CTSA) grant, UL1 ... National Center for Research Resources. "Community Engagement ...
... , TUESDAY, Oct. 27 (HealthDay News) -- Researchers are reporting ... D2 can eliminate vitamin D deficiency, and twice-monthly doses can ... , The dosage -- 50,000 international units (IU) every ... to be toxic, according to the study published in the ...
... ... and severe sciatica causes widespread disability, and represents a significant unmet medical ... new approach for reducing nerve root inflammation. This off-label treatment method, invented ... including new data from randomized, placebo-controlled studies. , ...
... , ... Emdeon,s vast reach across the U.S. healthcare industry with Susan G. Komen,s mission to ... ... partnership with Susan G. Komen for the Cure®, the world,s largest breast cancer advocacy ...
... Oct. 27 Health Fitness Corporation (NYSE Amex: FIT ... management solutions, will conduct a conference call to discuss its ... The call is scheduled for 4:30 p.m. ET on Wednesday, ... (412) 858-4600 to access the conference call, or can listen ...
... Oct. 27 , Robert A. Douglas, 1st ... , RJR Focus: SHC Career Division national sales growth, ... 20 years of previous sales management experience and over 6 ... SHC he has been fundamental in the development and implementation ...
Cached Medicine News:Health News:Tufts CTSI and Tufts University receive 4 NIH supplemental grant awards 2Health News:Tufts CTSI and Tufts University receive 4 NIH supplemental grant awards 3Health News:Short-Term, High-Dose Vitamin D2 May Ease Deficiency 2Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 2Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 3Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 4Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 2Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 3Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 4Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 2Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 3Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 4
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... , July 31, 2015  Xcelience, a ... that it has made a structured cash investment ... company specializing in milling, micronization and powder size ... help grow Powdersize,s business while simultaneously adding a ... Xcelience,s portfolio of capabilities. "As ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... announced that the US Food and Drug Administration (FDA) ... submissions for review of the investigational drug vandetanib in ... (MTC). The FDA also granted priority review status for ... User Fee Act (PDUFA) action date of 7 January ...
... RIVER, N.Y., Sept. 22 Netsmart Technologies, ... and services for health and human services ... prescribing and medication management system for behavioral ... from Surescripts®. Surescripts operates the ...
Cached Medicine Technology:US and EU Regulatory Submissions for Vandetanib in Advanced Medullary Thyroid Cancer Accepted for Review 2Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 2Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 3Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 4
Immersion Oil, 1,250 cs...
Immersion oil for microscopy...
... system is a compact, convenient and precise ... a significant improvement in life quality through ... condition. , , The CoaguChek XS system ... CoaguChek S system. It encompasses several innovative ...
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
Medicine Products: